Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-07-18

AUTHORS

Munemitsu Otagaki, Koichiro Matsumura, Hiromi Kin, Kenichi Fujii, Hiroki Shibutani, Hiroshi Matsumoto, Hiroki Takahashi, Haengnam Park, Yoshihiro Yamamoto, Tetsuro Sugiura, Ichiro Shiojima

ABSTRACT

PurposeRecent studies have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors have a favorable effect on cardiovascular events in diabetic patients. However, the underlying mechanism associated with a favorable outcome has not been clearly identified. The purpose of this study was to investigate the effect of tofogliflozin, SGLT2 inhibitor, on systolic and diastolic cardiac function in patients with type 2 diabetes mellitus (T2DM).MethodsWe enrolled 26 consecutive T2DM out-patients on glucose-lowering drugs who initiated tofogliflozin and underwent echocardiography before and ≥ 6 months after tofogliflozin administration. During this period, we also enrolled 162 T2DM out-patients taking other glucose-lowering drugs as a control group. Propensity score analysis was performed to match the patient characteristics. As a result, 42 patients (tofogliflozin group 21 patients and control group 21 patients) were finally used for analysis. Left ventricular systolic function was assessed by measuring 2D-echocardiographic left ventricular ejection fraction (LVEF) and diastolic cardiac function by pulsed wave Doppler-derived early diastolic velocity (E/e′).ResultsThere were no significant differences in patient characteristics and echocardiographic parameters at baseline. The change in LVEF from baseline to follow-up was 5.0 ± 6.9% in the tofogliflozin group and − 0.6 ± 5.5% in the control group; difference significant, p = 0.006. The change in E/e′ was − 1.7 ± 3.4 in the tofogliflozin group and 0.7 ± 4.1 in the control group; difference significant, p = 0.024.ConclusionsIn addition to conventional oral glucose-lowering drugs, additional tofogliflozin administration had a favorable effect on left ventricular systolic and diastolic function in patients with T2DM. More... »

PAGES

435-442

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10557-019-06892-y

DOI

http://dx.doi.org/10.1007/s10557-019-06892-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1118091071

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31321581


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzhydryl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diastole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucosides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardial Contraction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium-Glucose Transporter 2 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Systole", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Otagaki", 
        "givenName": "Munemitsu", 
        "id": "sg:person.012634224522.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012634224522.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumura", 
        "givenName": "Koichiro", 
        "id": "sg:person.011021307255.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011021307255.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kin", 
        "givenName": "Hiromi", 
        "id": "sg:person.012227342247.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012227342247.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujii", 
        "givenName": "Kenichi", 
        "id": "sg:person.01164156601.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164156601.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shibutani", 
        "givenName": "Hiroki", 
        "id": "sg:person.01164134065.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164134065.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Hiroshi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "Hiroki", 
        "id": "sg:person.013426706770.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013426706770.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Park", 
        "givenName": "Haengnam", 
        "id": "sg:person.01252462647.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252462647.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Yoshihiro", 
        "id": "sg:person.01366711247.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366711247.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sugiura", 
        "givenName": "Tetsuro", 
        "id": "sg:person.0706420742.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706420742.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shiojima", 
        "givenName": "Ichiro", 
        "id": "sg:person.0632605707.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632605707.34"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12933-018-0741-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105411630", 
          "https://doi.org/10.1186/s12933-018-0741-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-018-0775-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107488304", 
          "https://doi.org/10.1186/s12933-018-0775-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-017-0516-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084251150", 
          "https://doi.org/10.1186/s12933-017-0516-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10557-017-6724-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085052728", 
          "https://doi.org/10.1007/s10557-017-6724-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-018-0717-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104147789", 
          "https://doi.org/10.1186/s12933-018-0717-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10557-017-6741-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090851868", 
          "https://doi.org/10.1007/s10557-017-6741-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12020-012-9623-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015931238", 
          "https://doi.org/10.1007/s12020-012-9623-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-016-0489-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013379554", 
          "https://doi.org/10.1186/s12933-016-0489-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10557-017-6734-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086127767", 
          "https://doi.org/10.1007/s10557-017-6734-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-07-18", 
    "datePublishedReg": "2019-07-18", 
    "description": "PurposeRecent studies have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors have a favorable effect on cardiovascular events in diabetic patients. However, the underlying mechanism associated with a favorable outcome has not been clearly identified. The purpose of this study was to investigate the effect of tofogliflozin, SGLT2 inhibitor, on systolic and diastolic cardiac function in patients with type 2 diabetes mellitus (T2DM).MethodsWe enrolled 26 consecutive T2DM out-patients on glucose-lowering drugs who initiated tofogliflozin and underwent echocardiography before and \u2265\u20096\u00a0months after tofogliflozin administration. During this period, we also enrolled 162 T2DM out-patients taking other glucose-lowering drugs as a control group. Propensity score analysis was performed to match the patient characteristics. As a result, 42 patients (tofogliflozin group 21 patients and control group 21 patients) were finally used for analysis. Left ventricular systolic function was assessed by measuring 2D-echocardiographic left ventricular ejection fraction (LVEF) and diastolic cardiac function by pulsed wave Doppler-derived early diastolic velocity (E/e\u2032).ResultsThere were no significant differences in patient characteristics and echocardiographic parameters at baseline. The change in LVEF from baseline to follow-up was 5.0\u2009\u00b1\u20096.9% in the tofogliflozin group and \u2212\u20090.6\u2009\u00b1\u20095.5% in the control group; difference significant, p\u2009=\u20090.006. The change in E/e\u2032 was \u2212\u20091.7\u2009\u00b1\u20093.4 in the tofogliflozin group and 0.7\u2009\u00b1\u20094.1 in the control group; difference significant, p\u2009=\u20090.024.ConclusionsIn addition to conventional oral glucose-lowering drugs, additional tofogliflozin administration had a favorable effect on left ventricular systolic and diastolic function in patients with T2DM.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10557-019-06892-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1097576", 
        "issn": [
          "0920-3206", 
          "1573-7241"
        ], 
        "name": "Cardiovascular Drugs and Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "keywords": [
      "left ventricular ejection fraction", 
      "diastolic cardiac function", 
      "glucose-lowering drugs", 
      "effects of tofogliflozin", 
      "cardiac function", 
      "control group", 
      "tofogliflozin administration", 
      "tofogliflozin group", 
      "diabetic patients", 
      "patient characteristics", 
      "sodium-glucose cotransporter 2 inhibitors", 
      "glucose cotransporter 2 inhibitors", 
      "oral glucose-lowering drugs", 
      "type 2 diabetic patients", 
      "left ventricular systolic function", 
      "type 2 diabetes mellitus", 
      "cotransporter 2 inhibitors", 
      "ventricular systolic function", 
      "ventricular ejection fraction", 
      "early diastolic velocity", 
      "left ventricular systolic", 
      "favorable effect", 
      "propensity score analysis", 
      "cardiovascular events", 
      "underwent echocardiography", 
      "echocardiographic parameters", 
      "ventricular systolic", 
      "systolic function", 
      "diastolic function", 
      "diabetes mellitus", 
      "ejection fraction", 
      "SGLT2 inhibitors", 
      "diastolic velocity", 
      "favorable outcome", 
      "PurposeRecent studies", 
      "patients", 
      "wave Doppler", 
      "T2DM", 
      "systolic", 
      "tofogliflozin", 
      "score analysis", 
      "drugs", 
      "underlying mechanism", 
      "significant differences", 
      "administration", 
      "baseline", 
      "group", 
      "inhibitors", 
      "mellitus", 
      "echocardiography", 
      "ResultsThere", 
      "MethodsWe", 
      "differences", 
      "months", 
      "outcomes", 
      "effect", 
      "study", 
      "function", 
      "Doppler", 
      "changes", 
      "period", 
      "events", 
      "analysis", 
      "mechanism", 
      "characteristics", 
      "purpose", 
      "addition", 
      "-E", 
      "fraction", 
      "results", 
      "parameters", 
      "velocity"
    ], 
    "name": "Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients", 
    "pagination": "435-442", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1118091071"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10557-019-06892-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31321581"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10557-019-06892-y", 
      "https://app.dimensions.ai/details/publication/pub.1118091071"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-10T10:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_799.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10557-019-06892-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10557-019-06892-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10557-019-06892-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10557-019-06892-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10557-019-06892-y'


 

This table displays all metadata directly associated to this object as RDF triples.

289 TRIPLES      22 PREDICATES      119 URIs      102 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10557-019-06892-y schema:about N1d4c8d4671724baeaf0864f4981969ed
2 N4b20ecd2e77449d2b868433c59bb0af9
3 N4b480cd1b4e54ac096f7bc9b7d1496f3
4 N605292d7cdc94b3db5ced60f11b33fc3
5 N751f53f09bf9457ba9c233913fba01c1
6 N76d281a775c94eafab705b17e0d6f32c
7 N91b208f2469c4eca8a3c55ec036f9b15
8 N9ddeab75ba0b4d60a614ee3d79d165c2
9 Na475157d189e43cb9a319b119fa3ac69
10 Na55d994932b948e3affb2b9b314e1801
11 Nbf45df6914ab4975a05202b25898df88
12 Nebda92a5a766478cae975dbaeb73b6a0
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N382474fccd4b4d889b5b5dc898328885
16 schema:citation sg:pub.10.1007/s10557-017-6724-3
17 sg:pub.10.1007/s10557-017-6734-1
18 sg:pub.10.1007/s10557-017-6741-2
19 sg:pub.10.1007/s12020-012-9623-1
20 sg:pub.10.1186/s12933-016-0489-z
21 sg:pub.10.1186/s12933-017-0516-8
22 sg:pub.10.1186/s12933-018-0717-9
23 sg:pub.10.1186/s12933-018-0741-9
24 sg:pub.10.1186/s12933-018-0775-z
25 schema:datePublished 2019-07-18
26 schema:datePublishedReg 2019-07-18
27 schema:description PurposeRecent studies have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors have a favorable effect on cardiovascular events in diabetic patients. However, the underlying mechanism associated with a favorable outcome has not been clearly identified. The purpose of this study was to investigate the effect of tofogliflozin, SGLT2 inhibitor, on systolic and diastolic cardiac function in patients with type 2 diabetes mellitus (T2DM).MethodsWe enrolled 26 consecutive T2DM out-patients on glucose-lowering drugs who initiated tofogliflozin and underwent echocardiography before and ≥ 6 months after tofogliflozin administration. During this period, we also enrolled 162 T2DM out-patients taking other glucose-lowering drugs as a control group. Propensity score analysis was performed to match the patient characteristics. As a result, 42 patients (tofogliflozin group 21 patients and control group 21 patients) were finally used for analysis. Left ventricular systolic function was assessed by measuring 2D-echocardiographic left ventricular ejection fraction (LVEF) and diastolic cardiac function by pulsed wave Doppler-derived early diastolic velocity (E/e′).ResultsThere were no significant differences in patient characteristics and echocardiographic parameters at baseline. The change in LVEF from baseline to follow-up was 5.0 ± 6.9% in the tofogliflozin group and − 0.6 ± 5.5% in the control group; difference significant, p = 0.006. The change in E/e′ was − 1.7 ± 3.4 in the tofogliflozin group and 0.7 ± 4.1 in the control group; difference significant, p = 0.024.ConclusionsIn addition to conventional oral glucose-lowering drugs, additional tofogliflozin administration had a favorable effect on left ventricular systolic and diastolic function in patients with T2DM.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N368944b4ec774bfcbc8449ad1b97782d
32 N645a1ec4ba7c4f2d896bfe745ec25666
33 sg:journal.1097576
34 schema:keywords -E
35 Doppler
36 MethodsWe
37 PurposeRecent studies
38 ResultsThere
39 SGLT2 inhibitors
40 T2DM
41 addition
42 administration
43 analysis
44 baseline
45 cardiac function
46 cardiovascular events
47 changes
48 characteristics
49 control group
50 cotransporter 2 inhibitors
51 diabetes mellitus
52 diabetic patients
53 diastolic cardiac function
54 diastolic function
55 diastolic velocity
56 differences
57 drugs
58 early diastolic velocity
59 echocardiographic parameters
60 echocardiography
61 effect
62 effects of tofogliflozin
63 ejection fraction
64 events
65 favorable effect
66 favorable outcome
67 fraction
68 function
69 glucose cotransporter 2 inhibitors
70 glucose-lowering drugs
71 group
72 inhibitors
73 left ventricular ejection fraction
74 left ventricular systolic
75 left ventricular systolic function
76 mechanism
77 mellitus
78 months
79 oral glucose-lowering drugs
80 outcomes
81 parameters
82 patient characteristics
83 patients
84 period
85 propensity score analysis
86 purpose
87 results
88 score analysis
89 significant differences
90 sodium-glucose cotransporter 2 inhibitors
91 study
92 systolic
93 systolic function
94 tofogliflozin
95 tofogliflozin administration
96 tofogliflozin group
97 type 2 diabetes mellitus
98 type 2 diabetic patients
99 underlying mechanism
100 underwent echocardiography
101 velocity
102 ventricular ejection fraction
103 ventricular systolic
104 ventricular systolic function
105 wave Doppler
106 schema:name Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
107 schema:pagination 435-442
108 schema:productId N6945a9b40b984a3dad5f275e958c3042
109 N7fab130ad5f44fdf98424c4d5f480df1
110 Ne997050771244974b40187e8dc236add
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1118091071
112 https://doi.org/10.1007/s10557-019-06892-y
113 schema:sdDatePublished 2022-05-10T10:20
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher Nf73b29e7718b4eb0b72d4f5b4276ad9e
116 schema:url https://doi.org/10.1007/s10557-019-06892-y
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N098ec487ae5a4abfaa43eeeed10853b3 rdf:first sg:person.0706420742.40
121 rdf:rest Na321892df6d643868c51a17a45265b81
122 N0a98dd2128394921a1424b54937f3a16 rdf:first N3b4598a606974113a7fc421d7d02bac4
123 rdf:rest Nbbd3aba7d12148beb31e3cef65bd002f
124 N0f41111bc40c44329e11e356456e8960 rdf:first sg:person.01164134065.52
125 rdf:rest N0a98dd2128394921a1424b54937f3a16
126 N1d4c8d4671724baeaf0864f4981969ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Male
128 rdf:type schema:DefinedTerm
129 N3012684230154edfa9a439494d784046 rdf:first sg:person.012227342247.19
130 rdf:rest Nf977fca077ae4cbf93a6c2d9103b2983
131 N368944b4ec774bfcbc8449ad1b97782d schema:issueNumber 4
132 rdf:type schema:PublicationIssue
133 N382474fccd4b4d889b5b5dc898328885 rdf:first sg:person.012634224522.65
134 rdf:rest Nc2ca9114185945e5ad661acccbde58cd
135 N3b4598a606974113a7fc421d7d02bac4 schema:affiliation grid-institutes:grid.410783.9
136 schema:familyName Matsumoto
137 schema:givenName Hiroshi
138 rdf:type schema:Person
139 N432001663ae34981b80ade2a3a20e516 rdf:first sg:person.01252462647.18
140 rdf:rest N8013aaf451b241fcae5c8152b0c8a287
141 N4b20ecd2e77449d2b868433c59bb0af9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Diabetes Mellitus, Type 2
143 rdf:type schema:DefinedTerm
144 N4b480cd1b4e54ac096f7bc9b7d1496f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Sodium-Glucose Transporter 2 Inhibitors
146 rdf:type schema:DefinedTerm
147 N605292d7cdc94b3db5ced60f11b33fc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 N645a1ec4ba7c4f2d896bfe745ec25666 schema:volumeNumber 33
151 rdf:type schema:PublicationVolume
152 N6945a9b40b984a3dad5f275e958c3042 schema:name doi
153 schema:value 10.1007/s10557-019-06892-y
154 rdf:type schema:PropertyValue
155 N751f53f09bf9457ba9c233913fba01c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Diastole
157 rdf:type schema:DefinedTerm
158 N76d281a775c94eafab705b17e0d6f32c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Benzhydryl Compounds
160 rdf:type schema:DefinedTerm
161 N7fab130ad5f44fdf98424c4d5f480df1 schema:name dimensions_id
162 schema:value pub.1118091071
163 rdf:type schema:PropertyValue
164 N8013aaf451b241fcae5c8152b0c8a287 rdf:first sg:person.01366711247.60
165 rdf:rest N098ec487ae5a4abfaa43eeeed10853b3
166 N91b208f2469c4eca8a3c55ec036f9b15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Middle Aged
168 rdf:type schema:DefinedTerm
169 N9ddeab75ba0b4d60a614ee3d79d165c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Myocardial Contraction
171 rdf:type schema:DefinedTerm
172 Na321892df6d643868c51a17a45265b81 rdf:first sg:person.0632605707.34
173 rdf:rest rdf:nil
174 Na475157d189e43cb9a319b119fa3ac69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Aged
176 rdf:type schema:DefinedTerm
177 Na55d994932b948e3affb2b9b314e1801 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Systole
179 rdf:type schema:DefinedTerm
180 Nbbd3aba7d12148beb31e3cef65bd002f rdf:first sg:person.013426706770.11
181 rdf:rest N432001663ae34981b80ade2a3a20e516
182 Nbf45df6914ab4975a05202b25898df88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Glucosides
184 rdf:type schema:DefinedTerm
185 Nc2ca9114185945e5ad661acccbde58cd rdf:first sg:person.011021307255.31
186 rdf:rest N3012684230154edfa9a439494d784046
187 Ne997050771244974b40187e8dc236add schema:name pubmed_id
188 schema:value 31321581
189 rdf:type schema:PropertyValue
190 Nebda92a5a766478cae975dbaeb73b6a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Female
192 rdf:type schema:DefinedTerm
193 Nf73b29e7718b4eb0b72d4f5b4276ad9e schema:name Springer Nature - SN SciGraph project
194 rdf:type schema:Organization
195 Nf977fca077ae4cbf93a6c2d9103b2983 rdf:first sg:person.01164156601.70
196 rdf:rest N0f41111bc40c44329e11e356456e8960
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
201 schema:name Clinical Sciences
202 rdf:type schema:DefinedTerm
203 sg:journal.1097576 schema:issn 0920-3206
204 1573-7241
205 schema:name Cardiovascular Drugs and Therapy
206 schema:publisher Springer Nature
207 rdf:type schema:Periodical
208 sg:person.011021307255.31 schema:affiliation grid-institutes:grid.410783.9
209 schema:familyName Matsumura
210 schema:givenName Koichiro
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011021307255.31
212 rdf:type schema:Person
213 sg:person.01164134065.52 schema:affiliation grid-institutes:grid.410783.9
214 schema:familyName Shibutani
215 schema:givenName Hiroki
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164134065.52
217 rdf:type schema:Person
218 sg:person.01164156601.70 schema:affiliation grid-institutes:grid.410783.9
219 schema:familyName Fujii
220 schema:givenName Kenichi
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164156601.70
222 rdf:type schema:Person
223 sg:person.012227342247.19 schema:affiliation grid-institutes:grid.410783.9
224 schema:familyName Kin
225 schema:givenName Hiromi
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012227342247.19
227 rdf:type schema:Person
228 sg:person.01252462647.18 schema:affiliation grid-institutes:grid.410783.9
229 schema:familyName Park
230 schema:givenName Haengnam
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252462647.18
232 rdf:type schema:Person
233 sg:person.012634224522.65 schema:affiliation grid-institutes:grid.410783.9
234 schema:familyName Otagaki
235 schema:givenName Munemitsu
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012634224522.65
237 rdf:type schema:Person
238 sg:person.013426706770.11 schema:affiliation grid-institutes:grid.410783.9
239 schema:familyName Takahashi
240 schema:givenName Hiroki
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013426706770.11
242 rdf:type schema:Person
243 sg:person.01366711247.60 schema:affiliation grid-institutes:grid.410783.9
244 schema:familyName Yamamoto
245 schema:givenName Yoshihiro
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366711247.60
247 rdf:type schema:Person
248 sg:person.0632605707.34 schema:affiliation grid-institutes:grid.410783.9
249 schema:familyName Shiojima
250 schema:givenName Ichiro
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632605707.34
252 rdf:type schema:Person
253 sg:person.0706420742.40 schema:affiliation grid-institutes:grid.410783.9
254 schema:familyName Sugiura
255 schema:givenName Tetsuro
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706420742.40
257 rdf:type schema:Person
258 sg:pub.10.1007/s10557-017-6724-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085052728
259 https://doi.org/10.1007/s10557-017-6724-3
260 rdf:type schema:CreativeWork
261 sg:pub.10.1007/s10557-017-6734-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086127767
262 https://doi.org/10.1007/s10557-017-6734-1
263 rdf:type schema:CreativeWork
264 sg:pub.10.1007/s10557-017-6741-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090851868
265 https://doi.org/10.1007/s10557-017-6741-2
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s12020-012-9623-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015931238
268 https://doi.org/10.1007/s12020-012-9623-1
269 rdf:type schema:CreativeWork
270 sg:pub.10.1186/s12933-016-0489-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1013379554
271 https://doi.org/10.1186/s12933-016-0489-z
272 rdf:type schema:CreativeWork
273 sg:pub.10.1186/s12933-017-0516-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084251150
274 https://doi.org/10.1186/s12933-017-0516-8
275 rdf:type schema:CreativeWork
276 sg:pub.10.1186/s12933-018-0717-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104147789
277 https://doi.org/10.1186/s12933-018-0717-9
278 rdf:type schema:CreativeWork
279 sg:pub.10.1186/s12933-018-0741-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105411630
280 https://doi.org/10.1186/s12933-018-0741-9
281 rdf:type schema:CreativeWork
282 sg:pub.10.1186/s12933-018-0775-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1107488304
283 https://doi.org/10.1186/s12933-018-0775-z
284 rdf:type schema:CreativeWork
285 grid-institutes:grid.410783.9 schema:alternateName Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan
286 Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan
287 schema:name Department of Cardiology, Kansai Medical University Medical Center, 10-15, Fumizono-cho, 570-8507, Moriguchi, Osaka, Japan
288 Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan
289 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...